Your browser doesn't support javascript.
loading
Patient-derived xenografts for childhood solid tumors: a valuable tool to test new drugs and personalize treatments
Zarzosa, P; Navarro, N; Giralt, I; Molist, C; Almazán-Moga, A; Vidal, I; Soriano, A; Segura, MF; Hladun, R; Villanueva, A; Gallego, S; Roma, J.
Affiliation
  • Zarzosa, P; Hospital Universitari Vall d’Hebron. Laboratory of Translational Research in Childhood and Adolescent Cancer. Barcelona. Spain
  • Navarro, N; Hospital Universitari Vall d’Hebron. Laboratory of Translational Research in Childhood and Adolescent Cancer. Barcelona. Spain
  • Giralt, I; Hospital Universitari Vall d’Hebron. Laboratory of Translational Research in Childhood and Adolescent Cancer. Barcelona. Spain
  • Molist, C; Hospital Universitari Vall d’Hebron. Laboratory of Translational Research in Childhood and Adolescent Cancer. Barcelona. Spain
  • Almazán-Moga, A; Hospital Universitari Vall d’Hebron. Laboratory of Translational Research in Childhood and Adolescent Cancer. Barcelona. Spain
  • Vidal, I; Hospital Universitari Vall d’Hebron. Laboratory of Translational Research in Childhood and Adolescent Cancer. Barcelona. Spain
  • Soriano, A; Hospital Universitari Vall d’Hebron. Laboratory of Translational Research in Childhood and Adolescent Cancer. Barcelona. Spain
  • Segura, MF; Hospital Universitari Vall d’Hebron. Laboratory of Translational Research in Childhood and Adolescent Cancer. Barcelona. Spain
  • Hladun, R; Hospital Universitari Vall d’Hebron. Pediatric Oncology and Hematology Department. Barcelona. Spain
  • Villanueva, A; Catalan Institute of Oncology (ICO). Chemoresistance and Predicitive Factors Laboratory. Program Against Cancer Therapeutic Resistance (ProCURE). Barcelona. Spain
  • Gallego, S; Hospital Universitari Vall d’Hebron. Laboratory of Translational Research in Childhood and Adolescent Cancer. Barcelona. Spain
  • Roma, J; Hospital Universitari Vall d’Hebron. Laboratory of Translational Research in Childhood and Adolescent Cancer. Barcelona. Spain
Clin. transl. oncol. (Print) ; 19(1): 44-50, ene. 2017. tab, ilus
Article in English | IBECS | ID: ibc-159117
Responsible library: ES1.1
Localization: BNCS
ABSTRACT
The use of preclinical models is essential in translational cancer research and especially important in pediatric cancer given the low incidence of each particular type of cancer. Cell line cultures have led to significant advances in cancer biology. However, cell lines have adapted to growth in artificial culture conditions, thereby undergoing genetic and phenotypic changes which may hinder the translational application. Tumor grafts developed in mice from patient tumor tissues, generally known as patient-derived xenografts (PDXs), are interesting alternative approaches to reproducing the biology of the original tumor. This review is focused on highlighting the interest of PDX models in pediatric cancer research and supporting strategies of personalized medicine. This review provides (1) a description of the background of PDX in cancer, (2) the particular case of PDX in pediatric cancer, (3) how PDX can improve personalized medicine strategies, (4) new methods to increase engraftment, and, finally, (5) concluding remarks (AU)
RESUMEN
No disponible
Subject(s)
Search on Google
Add to My VHL
Print
XML

Collection: National databases / Spain Database: IBECS Main subject: Biopsy / In Vitro Techniques / Xenograft Model Antitumor Assays / Models, Animal / Disease Models, Animal / Translational Research, Biomedical / Neoplasms Type of study: Prognostic study Limits: Child / Female / Humans / Male Language: English Journal: Clin. transl. oncol. (Print) Year: 2017 Document type: Article Institution/Affiliation country: Catalan Institute of Oncology (ICO)/Spain / Hospital Universitari Vall d’Hebron/Spain
Search on Google
Add to My VHL
Print
XML

Collection: National databases / Spain Database: IBECS Main subject: Biopsy / In Vitro Techniques / Xenograft Model Antitumor Assays / Models, Animal / Disease Models, Animal / Translational Research, Biomedical / Neoplasms Type of study: Prognostic study Limits: Child / Female / Humans / Male Language: English Journal: Clin. transl. oncol. (Print) Year: 2017 Document type: Article Institution/Affiliation country: Catalan Institute of Oncology (ICO)/Spain / Hospital Universitari Vall d’Hebron/Spain